drugset
drugset / Trial / NCT01528137

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01528137 ↗

Phase 1 Terminated 4 enrolled Stanford University Agennix · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer. Biological therapies, such as talactoferrin, may stimulate the immune system in different ways and stop tumor cells from growing

Timeline

Start
2012-05
Primary completion
2012-08
Completion
2013-07

Outcome

Outcome not reported

Stopped: “Negative data from another trial led to termination of this trial by sponsor.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Talactoferrin alfa Protein / enzyme biologic — Oral

Indications

hypopharynx squamous cell carcinoma larynx verrucous carcinoma metastatic squamous cell carcinoma nasal cavity and paranasal sinus squamous cell carcinoma nasopharyngeal squamous cell carcinoma non-small cell lung carcinoma oropharynx squamous cell carcinoma salivary gland squamous cell carcinoma tongue cancer verrucous carcinoma of oral cavity